{"entity":{"id":"steven-le-gouill","kind":"person","name":"Steven Le Gouill","aka":[],"tldr":"Steven Le Gouill is a lymphoma specialist who leads the Institut Curie hospitals.","summary":"Steven Le Gouill is Director of the Institut Curie Hospital Group in Paris and a haematologist. His specialisms are lymphoma, mantle cell lymphoma and hospital leadership. He is a lymphoma trialist known for mantle cell lymphoma studies with the LYSA group. His papers include the long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma in the LYMA trial, the final results of a phase II study of acalabrutinib monotherapy in relapsed or refractory mantle cell lymphoma, and a Blood comparison of obinutuzumab and rituximab for transplant-eligible patients with mantle cell lymphoma. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20Gouill%20S%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-curie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["haematologica"],"dependsOn":[],"notes":[],"role":"Director, Institut Curie Hospital Group; haematologist","institutionId":"institut-curie","specialisms":["Lymphoma","Mantle cell lymphoma","Hospital leadership"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Le%20Gouill%20S%5BAuthor%5D%20mantle%20cell%20lymphoma"}],"papers":[{"title":"Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study","journal":"Journal of Clinical Oncology","year":2024,"doi":"10.1200/jco.23.01586"},{"title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors","journal":"Haematologica","year":2023,"doi":"10.3324/haematol.2022.282469"},{"title":"Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma","journal":"Blood","year":2024,"doi":"10.1182/blood.2024023944"}],"orcid":"0000-0001-9840-2128"},"route":"/people/steven-le-gouill/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"institution":[{"id":"institut-curie","kind":"institution","name":"Institut Curie","route":"/institutions/institut-curie/"}],"journal":[{"id":"haematologica","kind":"journal","name":"Haematologica","route":"/journals/haematologica/"}],"company":[{"id":"lysa","kind":"company","name":"LYSA (The Lymphoma Study Association)","route":"/companies/lysa/"}]}}